In this study we evaluate whether LDV/SOF together with either Cisplatin supplier ribavirin (RBV) or the non-nucleotide NS5B inhibitor GS-9669 would allow patients to achieve high rates of SVR when administered for a shorter duration of 8 weeks in patients

with cirrhosis. Methods: 100 compensated cirrhotic patients with chronic HCV genotype 1 infection were randomized in equal proportions to receive LDV/SOF+RBV, LDV/SOF+GS-9669 250 mg, or LDV/SOF+GS-9669 500 mg daily for 8 weeks. Results: 100 patients were randomized and treated. The majority were male (65%), Caucasian (92%), treatment-experienced (74%), and had HCV genotype 1a (62%), and IL28B non-CC genotype (82%). 25 had previously Akt inhibitor been treated with a protease inhibitor+PEG+RBV regimen. The median BMI was 28.9 kg/m2 and the median HCV RNA was 6.1 log10 IU/ml. SVR12 rates are shown in the table. LDV/SOF+RBV or +GS-9669 was safe and well tolerated. There were two SAEs. One patient discontinued study

treatment due to an exacerbation of preexisting CHF. Adverse events were generally mild, and Grade 3/4 laboratory abnormalities were infrequent. The most frequent adverse events were headache, diarrhea, and nausea; both headache and nausea were most frequent in the LDV/SOF+500 mg GS-9669 group. Conclusions: Ledipasvir/sofosbuvir together with RBV or GS-9669 was effective in treating HCV. Overall 87% of patients achieved SVR12. Coadministration of GS-9669 did not appear to provide additional efficacy compared to RBV. To shorten therapy further or achieve higher selleckchem rates of SVR a more

potent agent or one with a complimentary mechanism of action may be required. All regimens were safe and well tolerated. Disclosures: Eric Lawitz – Advisory Committees or Review Panels: AbbVie, Achillion Pharmaceuticals, BioCryst, Biotica, Enanta, Idenix Pharmaceuticals, Janssen, Merck & Co, Novartis, Santaris Pharmaceuticals, Theravance, Vertex Pharmaceuticals; Grant/Research Support: AbbVie, Achillion Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Idenix Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Merck & Co, Novartis, Presidio, Roche, Santaris Pharmaceuticals, Vertex Pharmaceuticals ; Speaking and Teaching: Gilead, Kadmon, Merck, Vertex Fred Poordad – Advisory Committees or Review Panels: Abbott, Achillion, BMS, Inhibitex, Boeheringer Ingelheim, Pfizer, Genentech, Idenix, Gilead, Merck, Vertex, Salix, Janssen, Novartis; Grant/Research Support: Abbott, Anadys, Achillion, BMS, Boehringer Ingelheim, Genentech, Idenix, Gilead, Merck, Phar-massett, Vertex, Salix, Tibotec/Janssen, Novartis Robert H. Hyland – Employment: Gilead Sciences, Inc; Stock Shareholder: Gilead Sciences, Inc Jing Wang – Employment: Gilead Science Phillip S.